Ekso Bionics Holdings Inc (EKSO) - Total Liabilities
Based on the latest financial reports, Ekso Bionics Holdings Inc (EKSO) has total liabilities worth $13.93 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Ekso Bionics Holdings Inc growing its equity to track the company's year-over-year net asset growth rate.
Ekso Bionics Holdings Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Ekso Bionics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data.
Ekso Bionics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Ekso Bionics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hastings Technology Metals Ltd
AU:HAS
|
Australia | AU$137.26 Million |
|
EPE Capital Partners Ltd
JSE:EPE
|
South Africa | ZAC29.24 Million |
|
Farm Pride Foods Ltd
AU:FRM
|
Australia | AU$43.54 Million |
|
Azimut Exploration Inc.
V:AZM
|
Canada | CA$6.74 Million |
|
Brand Group (M.G) Ltd
TA:BRND
|
Israel | ILA615.29 Million |
|
Canlan Ice Sports Corp.
TO:ICE
|
Canada | CA$80.61 Million |
|
Infrea AB
ST:INFREA
|
Sweden | Skr523.60 Million |
|
Hana Must SPAC 2
KQ:208370
|
Korea | ₩6.87 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Ekso Bionics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ekso Bionics Holdings Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ekso Bionics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ekso Bionics Holdings Inc (2011–2025)
The table below shows the annual total liabilities of Ekso Bionics Holdings Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.08 Million | -20.52% |
| 2024-12-31 | $13.95 Million | -14.51% |
| 2023-12-31 | $16.31 Million | +5.50% |
| 2022-12-31 | $15.46 Million | +29.41% |
| 2021-12-31 | $11.95 Million | -26.08% |
| 2020-12-31 | $16.16 Million | +6.91% |
| 2019-12-31 | $15.12 Million | +1.28% |
| 2018-12-31 | $14.93 Million | -10.06% |
| 2017-12-31 | $16.60 Million | -7.25% |
| 2016-12-31 | $17.89 Million | -23.50% |
| 2015-12-31 | $23.39 Million | +119.13% |
| 2014-12-31 | $10.67 Million | +75473.49% |
| 2013-12-31 | $14.12K | 0.00% |
| 2012-12-31 | $14.12K | +74.37% |
| 2011-12-31 | $8.10K | -- |
About Ekso Bionics Holdings Inc
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It … Read more